NASDAQ:ABUS

Arbutus Biopharma Stock Forecast

etoro logo Buy ABUS
*Your capital is at risk
$4.52
-0.0300 (-0.659%)
At Close: Jun 22, 2026
AI Analysis AI Analysis of ABUS AI-Powered Market Insights
Stock Analysis PRO New!
Risk Assessment PRO New!
Trading Strategy PRO New!
Add ABUS to Watchlist?
Some Reasons Why To Add ABUS:
  • High gross margin of 100.0%
  • Strong operating margin of 80.8%
  • Healthy interest coverage ratio of 1,798.5x
PDF

Evaluation of Arbutus Biopharma Corporation stock downgraded after the last trading session
(Updated on Jun 22, 2026)

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Sell candidate since Jun 22, 2026

The Arbutus Biopharma Corporation stock price fell by -0.659% on the last day (Monday, 22nd Jun 2026) from $4.55 to $4.52. During the last trading day the stock fluctuated 7.25% from a day low at $4.47 to a day high of $4.79. The price has risen in 6 of the last 10 days and is up by 6.35% over the past 2 weeks. Volume has increased on the last day by 313 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 5 million shares were bought and sold for approximately $23.72 million.

The stock is moving within a wide and horizontal trend and further movements within this trend can be expected. Given the current horizontal trend, you can expect Arbutus Biopharma Corporation stock with a 90% probability to be traded between $4.05 and $4.63 at the end of this 3-month period. A break of a horizontal trend is often followed by a large increase in the volume, and stocks seldom manage to go directly from the bottom of a trend up to the top. Stocks turning up in the middle of a horizontal trend are therefore considered to be potential runners.

ABUS Signals & Forecast

There are mixed signals in the stock today. A sell signal was issued from a pivot top point on Thursday, June 18, 2026, and so far it has fallen -0.659%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely. The Arbutus Biopharma Corporation stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $4.39 and $4.37. A breakdown below any of these levels will issue sell signals.

Buy
Special Signal Notification

Double Bottom Formation

Double Bottom Formation A buy signal from a double bottom formation was found on Wednesday, April 29, 2026 and based on theory for this formation the price should go up by 11.90% to $5.06 within 13 trading days (Monday, May 18, 2026) since signal was issued.

Support, Risk & Stop-loss for Arbutus Biopharma Corporation stock

Arbutus Biopharma Corporation finds support from accumulated volume at $4.42 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.324 between high and low, or 7.25%. For the last week, the stock has had daily average volatility of 4.04%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (ABUS) For The Upcoming Trading Day Of Tuesday 23rd

For the upcoming trading day on Tuesday, 23rd we expect Arbutus Biopharma Corporation to open at $4.59, and during the day (based on 14 day Average True Range), to move between $4.43 and $4.61, which gives a possible trading interval of +/-$0.180 (+/-4.07%) up or down from last closing price. If Arbutus Biopharma Corporation takes out the full calculated possible swing range there will be an estimated 4.07% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $4.53 (0.22%) than the support at $4.42 (2.21%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Arbutus Biopharma Corporation stock A Buy?

Arbutus Biopharma Corporation holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Sell candidate.

Current score: -1.356 Sell Candidate Downgraded

Predicted Fair Opening Price

Predicted fair opening price on June 23, 2026 - $4.59 ( 1.58%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* eToro
*Your capital is at risk

ABUS Performance

Trading levels for ABUS

StockInvest.us
Full Access. No Commitment. 7 Days Free!
Long & Short-Term Golden Star Lists
AI Stock Analysis*
Top 10 Candidates on Every List
Premium Lists
Ad-FREE Browsing
Advanced Stock Screener

Fibonacci Support & Resistance Levels

Level Price
R3 4.92 8.74%
R2 4.79 6.01%
R1 4.72 4.31%
Price 4.52
S1 4.47 -1.16%
S2 4.39 -2.85%
S3 4.27 -5.59%

Accumulated Volume Support & Resistance Levels

Level Price
R3 4.64 2.65%
R2 4.55 0.664%
R1 4.53 0.221%
Price 4.52
S1 4.42 -2.21%
S2 4.25 -5.97%
S3 4.20 -7.08%

FAQ

What is the symbol for Arbutus Biopharma Corporation Stock and on which exchange is it traded?
The symbol for Arbutus Biopharma Corporation is ABUS and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Arbutus Biopharma Corporation Stock?
Arbutus Biopharma Corporation holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Sell candidate.

How to buy Arbutus Biopharma Corporation Stock?
Arbutus Biopharma Corporation Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Arbutus Biopharma Corporation Stock.

What's the current price of Arbutus Biopharma Corporation Stock?
As of the end of day on the Jun 22, 2026, the price of an Arbutus Biopharma Corporation (ABUS) share was $4.52.

What is the 52-week high and low for Arbutus Biopharma Corporation Stock?
The 52-week high for Arbutus Biopharma Corporation Stock is $5.10 and the 52-week low is $3.04.

What is the market capitalization of Arbutus Biopharma Corporation Stock?
As of the Jun 22, 2026, the market capitalization of Arbutus Biopharma Corporation is 892.87M.

When is the next earnings date for Arbutus Biopharma Corporation?
The upcoming earnings date for Arbutus Biopharma Corporation is Aug 05, 2026.
Click to get the best stock tips daily for free!
ABOUT ARBUTUS BIOPHARMA CORPORATION
Arbutus Biopharma
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel ...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
18.12% Jun 12
DHI
$146.71
6.29% Jun 10
PHM
$118.49
6.02% Jun 10
EAT
$140.46
17.09% Jun 05
E
ETD
$20.67
3.19% Jun 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE